国家儿童健康与疾病临床医学研究中心 中华医学会儿科学分会感染学组 上海市医学会感染病分会. 儿童呼吸道合胞病毒感染临床诊治中国专家共识(2023年版)[J]. 临床儿科杂志, 2024, 42(1): 1-14.
表1
呼吸道合胞病毒感染的实验室诊断方法"
方法 | 类 型 | 灵敏度/% | 特异性/% | 检测时间 | 备 注 |
---|---|---|---|---|---|
核酸检测 | 快速核酸检测法 | 90.6~100 | 99.4~100 | 13 min~1 h | 新的主流方法;注意它在检测临床上低水平病毒滴度时可能过于敏感;需定时通过外部质量评估化验性能 |
传统核酸检测 | 86.4~100 | 97.7~100 | 1~8 h | ||
抗原检测 | 快速抗原 | 72.4~90.0 | 89.5~100 | <0.5 h | 一代的灵敏度有限;自动化测试提供了更好的性能;阴性标本应采用其他方法进行验证 |
病毒培养 | 直接免疫荧光法 | 93.5~94.1 | 96.8~99.8 | 1~4 h | 需收集适当数量的上皮细胞 |
快速病毒培养 | - | - | 1~2 d | 传统上被认为是金标准;许多因素影响病毒分离的成功 | |
病毒培养 | - | - | 3~7 d |
[1] |
Li Y, Wang X, Blau DM, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis[J]. Lancet, 2022, 399(10340): 2047-2064.
doi: 10.1016/S0140-6736(22)00478-0 pmid: 35598608 |
[2] |
Shi T, McAllister DA, O’Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study[J]. Lancet, 2017, 390(10098): 946-958.
doi: S0140-6736(17)30938-8 pmid: 28689664 |
[3] | 谢嘉慧, 邝璐, 钟家禹, 等. 2018年至2021年广州地区儿童急性呼吸道感染病原体的流行特征[J]. 中华传染病杂志, 2023, 41(2): 137-143. |
[4] |
Hu XW, Zhou Y, Yi S, 等. Epidemiological characteristics of respiratory syncytial virus infection among hospitalized children with acute respiratory tract infections from 2014 to 2022 in a hospital in hubei province, china: longitudinal surveillance study[J]. JMIR Public Health Surveill, 2023, 9: e43941.
doi: 10.2196/43941 |
[5] | Bénet T, Sánchez Picot V, Messaoudi M, et al. Micro-organisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study[J]. Clin Infect Dis, 2017, 65(4): 604-612. |
[6] |
Liu YN, Zhang YF, Xu Q, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study[J]. Lancet Microbe, 2023, 4(5): e330-e339.
doi: 10.1016/S2666-5247(23)00031-9 |
[7] |
O’Brien KL, Baggett HC, Brooks WA, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study[J]. Lancet, 2019, 394(10200): 757-779.
doi: S0140-6736(19)30721-4 pmid: 31257127 |
[8] |
Global Burden of Disease Pediatrics Collaboration, Kyu HH, Pinho C, et al. Global and National Burden of Diseases and injuries among children and adolescents between 1990 and 2013: findings from the global burden of disease 2013 study[J]. JAMA Pediatr, 2016, 170(3): 267.
doi: 10.1001/jamapediatrics.2015.4276 pmid: 26810619 |
[9] | 朱云, 卢根, 靳蓉, 等. 2017—2020年我国儿童急性下呼吸道感染住院病例中呼吸道合胞病毒的感染情况分析[J]. 中华预防医学杂志, 2022, 56(12): 1739-1744. |
[10] | 庄士豪, 曾玫, 徐锦, 等. 上海地区住院患儿呼吸道合胞病毒相关急性下呼吸道感染的流行病学调查[J]. 中华传染病杂志, 2022, 40(12): 735-741. |
[11] | Tabor DE, Fernandes F, Langedijk AC, et al. Global molecular epidemiology of respiratory syncytial virus from the 2017-2018 INFORM-RSV study[J]. J Clin Microbiol, 2020, 59(1): e01828-20. |
[12] |
Zhang S, Akmar LZ, Bailey F, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: a systematic review and meta-analysis[J]. J Infect Dis, 2020, 222(Suppl 7): S680-S687.
doi: 10.1093/infdis/jiz683 pmid: 32227101 |
[13] |
Suryadevara M, Domachowske JB. Epidemiology and seasonality of childhood respiratory syncytial virus infections in the tropics[J]. Viruses, 2021, 13(4): 696.
doi: 10.3390/v13040696 |
[14] |
Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview[J]. J Infect Dis, 2018, 217(9): 1356-1364.
doi: 10.1093/infdis/jiy056 pmid: 29390105 |
[15] |
Lam TT, Tang JW, Lai FY, et al. Comparative global epidemiology of influenza, respiratory syncytial and parainfluenza viruses, 2010-2015 [J]. J Infect, 2019, 79(4): 373-382.
doi: S0163-4453(19)30218-X pmid: 31323249 |
[16] |
Eden JS, Sikazwe C, Xie R, et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions[J]. Nat Commun, 2022, 13(1): 2884.
doi: 10.1038/s41467-022-30485-3 |
[17] |
Bardsley M, Morbey RA, Hughes HE, et al. Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study[J]. Lancet Infect Dis, 2023, 23(1): 56-66.
doi: 10.1016/S1473-3099(22)00525-4 |
[18] | Williams TC, Sinha I, Barr IG, et al. Transmission of paediatric respiratory syncytial virus and influenza in the wake of the COVID-19 pandemic[J]. Euro Surveill, 2021, 26(29): 2100186. |
[19] | Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic[J]. Pediatrics, 2021, 148(3): e2021052089. |
[20] |
Reicherz F, Xu RY, Abu-Raya B, et al. Waning immunity against respiratory syncytial virus during the coronavirus disease 2019 pandemic[J]. J Infect Dis, 2022, 226(12): 2064-2068.
doi: 10.1093/infdis/jiac192 |
[21] |
den Hartog G, van Kasteren PB, Schepp RM, et al. Decline of RSV-specific antibodies during the COVID-19 pandemic[J]. Lancet Infect Dis, 2023, 23(1): 23-25.
doi: 10.1016/S1473-3099(22)00763-0 |
[22] |
Zheng Z, Pitzer VE, Shapiro ED, et al. Estimation of the timing and intensity of reemergence of respiratory syncytial virus following the COVID-19 pandemic in the US[J]. JAMA Network Open, 2021, 4(12): e2141779.
doi: 10.1001/jamanetworkopen.2021.41779 |
[23] |
Hatter L, Eathorne A, Hills T, et al. Respiratory syncytial virus: paying the immunity debt with interest[J]. Lancet Child Adolesc Health, 2021, 5(12): e44-e45.
doi: 10.1016/S2352-4642(21)00333-3 |
[24] |
Piedimonte G, Perez MK. Respiratory syncytial virus infection and bronchiolitis[J]. Pediatr Rev, 2014, 35(12): 519-530.
doi: 10.1542/pir.35-12-519 pmid: 25452661 |
[25] |
Walsh EE. Respiratory syncytial virus infection: an illness for all ages[J]. Clin Chest Med, 2017, 38(1): 29-36.
doi: S0272-5231(16)30131-9 pmid: 28159159 |
[26] |
Houben ML, Bont L, Wilbrink B, et al. Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study[J]. Pediatrics, 2011, 127(1): 35-41.
doi: 10.1542/peds.2010-0581 pmid: 21187309 |
[27] |
Hall CB, Geiman JM, Biggar R, et al. Respiratory syncytial virus infections within families[J]. NEJM, 1976, 294(8): 414-419.
doi: 10.1056/NEJM197602192940803 |
[28] |
Henderson FW, Collier AM, Clyde WA, et al. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children[J]. NEJM, 1979, 300(10): 530-534.
doi: 10.1056/NEJM197903083001004 |
[29] |
Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis[J]. Lancet, 2017, 389(10065): 211-224.
doi: S0140-6736(16)30951-5 pmid: 27549684 |
[30] |
Meissner HC. Viral Bronchiolitis in Children[J]. NEJM, 2016, 374(1): 62-72.
doi: 10.1056/NEJMra1413456 |
[31] |
Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review[J]. J Pediatr, 2009, 155(5): 728-733.
doi: 10.1016/j.jpeds.2009.04.063 |
[32] |
Chatterjee A, Mavunda K, Krilov LR. Current state of respiratory syncytial virus disease and management[J]. Infect Dis Ther, 2021, 10(Suppl 1): 5-16.
doi: 10.1007/s40121-020-00387-2 |
[33] |
Manzoni P, Figueras-Aloy J, Simões EAF, et al. Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases[J]. Infect Dis Ther, 2017, 6(3): 383-411.
doi: 10.1007/s40121-017-0160-3 pmid: 28653300 |
[34] |
Kang JM, Lee J, Kim YK, et al. Pediatric intensive care unit admission due to respiratory syncytial virus: retrospective multicenter study[J]. Pediatr Int, 2019, 61(7): 688-696.
doi: 10.1111/ped.v61.7 |
[35] |
Playfor SD, Khader A. Arrhythmias associated with respiratory syncytial virus infection[J]. Pediatr Anesth, 2005, 15(11): 1016-1018.
pmid: 16238569 |
[36] |
Menchise A. Myocarditis in the setting of RSV bronchiolitis[J]. Fetal Pediatr Pathol, 2011, 30(1): 64-68.
doi: 10.3109/15513815.2010.505632 pmid: 21204669 |
[37] |
Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review[J]. Crit Care, 2006, 10(4): R107.
doi: 10.1186/cc4984 |
[38] |
Saravanos GL, King CL, Deng L, et al. Respiratory syncytial virus-associated neurologic complications in children: a systematic review and aggregated case series[J]. J Pediatr, 2021, 239: 39-49.
doi: 10.1016/j.jpeds.2021.06.045 |
[39] | Hambling MH. Survival of the respiratory syncytial virus during storage under various conditions[J]. Br J Exp Pathol, 1964, 45(6): 647-655. |
[40] |
Gharabaghi F, Hawan A, Drews SJ, et al. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children[J]. Clin Microbiol Infect, 2011, 17(12): 1900-1906.
doi: 10.1111/j.1469-0691.2011.03529.x |
[41] |
Aslanzadeh J, Zheng X, Li H, et al. Prospective evaluation of rapid antigen tests for diagnosis of respiratory syncytial virus and human metapneumovirus infections[J]. J Clin Microbiol, 2008, 46(5): 1682-1685.
doi: 10.1128/JCM.00008-08 pmid: 18337386 |
[42] |
Schwartz RH, Selvarangan R, Zissman EN. BD veritor system respiratory syncytial virus rapid antigen detection test: point-of-care results in primary care pediatric offices compared with reverse transcriptase polymerase chain reaction and viral culture methods[J]. Pediatr Emerg Care, 2015, 31(12): 830-834.
doi: 10.1097/PEC.0000000000000371 pmid: 25803752 |
[43] |
Ginocchio CC, Swierkosz E, McAdam AJ, et al. Multicenter study of clinical performance of the 3M Rapid Detection RSV test[J]. J Clin Microbiol, 2010, 48(7): 2337-2343.
doi: 10.1128/JCM.00130-10 pmid: 20463154 |
[44] |
Selvarangan R, Abel D, Hamilton M. Comparison of BD DirectigenTM EZ RSV and Binax NOW® RSV tests for rapid detection of respiratory syncytial virus from nasopharyngeal aspirates in a pediatric population[J]. Diagn Microbiol Infect Dis, 2008, 62(2): 157-161.
doi: 10.1016/j.diagmicrobio.2008.05.005 |
[45] |
Liao RS, Tomalty LL, Majury A, et al. Comparison of viral isolation and multiplex real-time reverse transcription-PCR for confirmation of respiratory syncytial virus and influenza virus detection by antigen immunoassays[J]. J Clin Microb, 2009, 47(3): 527-532.
doi: 10.1128/JCM.01213-08 |
[46] |
Jonckheere S, Verfaillie C, Boel A, et al. Multicenter evaluation of BD Veritor System and RSV K-SeT for rapid detection of respiratory syncytial virus in a diagnostic laboratory setting[J]. Diagn Microbiol Infect Dis, 2015, 83(1): 37-40.
doi: 10.1016/j.diagmicrobio.2015.05.012 |
[47] |
Piché-Renaud PP, Turcot J, Chartrand C, et al. Evaluation of a fluorescent immunoassay rapid test (SofiaTM) for detection of influenza A+B and RSV in a tertiary pediatric setting[J]. Diagn Microbiol Infect Dis, 2016, 84(4): 304-308.
doi: 10.1016/j.diagmicrobio.2015.10.025 |
[48] |
Souza C, Zanchin NI, Krieger MA, et al. In silico analysis of amino acid variation in human respiratory syncytial virus: insights into immunodiagnostics[J]. Mem Inst Oswaldo Cruz, 2017, 112(10): 655-663.
doi: 10.1590/0074-02760170013 |
[49] |
Teirlinck AC, Broberg EK, Stuwitz Berg A, et al. Recommendations for respiratory syncytial virus surveillance at the national level[J]. Eur Respir J, 2021, 58(3): 2003766.
doi: 10.1183/13993003.03766-2020 |
[50] |
Salez N, Nougairede A, Ninove L, et al. Prospective and retrospective evaluation of the Cepheid Xpert® Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus[J]. Diagn Microbiol Infect Dis, 2015, 81(4): 256-258.
doi: 10.1016/j.diagmicrobio.2015.01.008 |
[51] |
Popowitch EB, Miller MB. Performance characteristics of Xpert Flu/RSV XC assay[J]. J Clin Microbiol, 2015, 53(8): 2720-2721.
doi: 10.1128/JCM.00972-15 pmid: 26019209 |
[52] | Banerjee D, Kanwar N, Hassan F, et al. Comparison of six sample-to-answer influenza a/b and respiratory syncytial virus nucleic acid amplification assays using respiratory specimens from children[J]. J Clin Microbiol, 2018, 56(11): e00930-18. |
[53] |
Cho CH, Lee CK, Nam MH, et al. Evaluation of the AdvanSureTM real-time RT-PCR compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses[J]. Diagn Microbiol Infect Dis, 2014, 79(1): 14-18.
doi: 10.1016/j.diagmicrobio.2014.01.016 |
[54] | Berbers G, Mollema L, van der Klis F, et al. Antibody responses to respiratory syncytial virus: a cross-sectional serosurveillance study in the dutch population focusing on infants younger than 2 years[J]. J Allergy Infect Dis, 2021, 224(2): 269-278. |
[55] | Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus[J]. J Infect Dis Med, 1991, 163(4): 693-698. |
[56] |
Murphy BR, Alling DW, Snyder MH, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection[J]. J Clin Microbiol, 1986, 24(5): 894-898.
doi: 10.1128/jcm.24.5.894-898.1986 pmid: 3771779 |
[57] |
Popow-Kraupp T, Lakits E, Kellner G, et al. Immuno-globulin-class-specific immune response to respiratory syncytial virus structural proteins in infants, children, and adults[J]. J Med Virol, 1989, 27(3): 215-223.
pmid: 2723614 |
[58] |
Popow-Kraupp T. Diagnosis of respiratory syncytial virus infection[J]. Open Microb J, 2011, 5(1): 128-134.
doi: 10.2174/1874285801105010128 |
[59] | Walsh EE, Peterson DR, Kalkanoglu AE, et al. Viral shedding and immune responses to respiratory syncytial virus infection in older adults[J]. J Infect Dis Med, 2013, 207(9): 1424-1432. |
[60] |
Wathuo M, Medley GF, Nokes DJ, et al. Quantification and determinants of the amount of respiratory syncytial virus (RSV) shed using real time PCR data from a longitudinal household study[J]. Wellcome Open Res, 2017, 1: 27.
doi: 10.12688/wellcomeopenres |
[61] | Richardson L, Brite J, Del Castillo M, et al. Comparison of respiratory virus shedding by conventional and molecular testing methods in patients with haematological malignancy[J]. Clin Microbiol Infect, 2016, 22(4): 380. |
[62] | Shafik CF, Mohareb EW, Youssef FG. Comparison of direct fluorescence assay and real-time RT-PCR as diagnostics for respiratory syncytial virus in young children[J]. J Trop Med, 2011, 2011: 1-3. |
[63] |
Blaschke AJ, McKevitt M, Ampofo K, et al. Midturbinate swabs are comparable to nasopharyngeal swabs for quantitative detection of respiratory syncytial virus in infants[J]. J Pediatr Infect Dis Soc, 2019, 8(6): 554-558.
doi: 10.1093/jpids/piy115 |
[64] |
Daley P, Castriciano S, Chernesky M, et al. Comparison of flocked and rayon swabs for collection of respiratory epithelial cells from uninfected volunteers and symptomatic patients[J]. J Clin Microbiol, 2006, 44(6): 2265-2267.
pmid: 16757636 |
[65] |
Wouters Y, Keyaerts E, Rector A, et al. Comparison of the IdyllaTM Respiratory (IFV-RSV) panel with the GeneXpert Xpert® Flu/RSV assay: a retrospective study with nasopharyngeal and midturbinate samples[J]. Diagn Microbiol Infect Dis, 2019, 94(1): 33-37.
doi: 10.1016/j.diagmicrobio.2018.11.022 |
[66] |
Macfarlane P, Denham J, Assous J, et al. RSV testing in bronchiolitis: which nasal sampling method is best?[J]. Arch Dis Child, 2005, 90(6): 634-635.
pmid: 15908632 |
[67] |
Mackenzie GA, Vilane A, Salaudeen R, et al. Respiratory syncytial, parainfluenza and influenza virus infection in young children with acute lower respiratory infection in rural Gambia[J]. Sci Rep, 2019, 9(1): 17965.
doi: 10.1038/s41598-019-54059-4 pmid: 31784567 |
[68] | Mandelberg A, Amirav I. Hypertonic saline or high volume normal saline for viral bronchiolitis: mechanisms and rationale: hypertonic saline[J]. Pediatr Pulmonl, 2010, 45(1): 36-40. |
[69] | Morikawa Y, Miura M, Furuhata MY, et al. Nebulized hypertonic saline in infants hospitalized with moderately severe bronchiolitis due to RSV infection: A multicenter randomized controlled trial[J]. Pediatr Pulmonl, 2018, 53(3): 358-365. |
[70] | Pandit P, Hoque MA, Pandit H, et al. Efficacy of nebulized hypertonic saline (3%) versus normal saline and salbutamol in treating acute bronchiolitis in a tertiary hospital: a randomized controlled trial[J]. MMJ, 2022, 31(2): 295-303. |
[71] |
Brooks CG, Harrison WN, Ralston SL. Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis: a reanalysis of 2 meta-analyses[J]. JAMA Pediatr, 2016, 170(6): 577-584.
doi: 10.1001/jamapediatrics.2016.0079 pmid: 27088767 |
[72] |
Angoulvant F, Bellêttre X, Milcent K, et al. Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: a randomized clinical trial[J]. JAMA Pediatr, 2017, 171(8): e171333.
doi: 10.1001/jamapediatrics.2017.1333 |
[73] |
Lin J, Zhang Y, Song A, et al. Exploring the appropriate dose of nebulized hypertonic saline for bronchiolitis: a dose-response meta-analysis[J]. J Invest Med, 2022, 70(1): 46-54.
doi: 10.1136/jim-2021-001947 |
[74] |
Hsieh CW, Chen C, Su HC, et al. Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials[J]. BMC Pediatr, 2020, 20(1): 434.
doi: 10.1186/s12887-020-02314-3 |
[75] |
Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis[J]. Pediatrics, 2014, 134(5): e1474-e1502.
doi: 10.1542/peds.2014-2742 |
[76] | National Collaborating Centre for Women’s and Children’s Health (UK). Bronchiolitis: diagnosis and management of bronchiolitis in children[M]. London: National Institute for Health and Care Excellence (NICE), 2015. |
[77] |
Cunningham S, Rodriguez A, Adams T, et al. Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial[J]. Lancet, 2015, 386(9998): 1041-1048.
doi: 10.1016/S0140-6736(15)00163-4 pmid: 26382998 |
[78] |
Dysart K, Miller TL, Wolfson MR, et al. Research in high flow therapy: mechanisms of action[J]. Resp Med, 2009, 103(10): 1400-1405.
doi: 10.1016/j.rmed.2009.04.007 |
[79] |
Sinha IP, McBride AKS, Smith R, et al. CPAP and high-flow nasal cannula oxygen in bronchiolitis[J]. Chest, 2015, 148(3): 810-823.
doi: S0012-3692(15)50661-2 pmid: 25836649 |
[80] |
Ramnarayan P, Richards-Belle A, Drikite L, et al. Effect of high-flow nasal cannula therapy vs continuous positive airway pressure therapy on liberation from respiratory support in acutely ill children admitted to pediatric critical care units: a randomized clinical trial[J]. JAMA, 2022, 328(2): 162-172.
doi: 10.1001/jama.2022.9615 pmid: 35707984 |
[81] |
Groupe Francophone de Réanimation et d’Urgences Pédiatriques (GFRUP), Milési C, Essouri S, et al. High flow nasal cannula (HFNC) versus nasal continuous positive airway pressure (nCPAP) for the initial respiratory management of acute viral bronchiolitis in young infants: a multicenter randomized controlled trial (TRAMONTANE study)[J]. Intensive Care Med, 2017, 43(2): 209-216.
doi: 10.1007/s00134-016-4617-8 pmid: 28124736 |
[82] |
Schlapbach L J, Schaefer J, Brady A M, et al. High-flow nasal cannula (HFNC) support in interhospital transport of critically ill children[J]. Intensive Care Med, 2014, 40(4): 592-599.
doi: 10.1007/s00134-014-3226-7 pmid: 24531340 |
[83] |
Garzon LS, Wiles L. Management of respiratory syncytial virus with lower respiratory tract infection in infants and children[J]. AACN Clin Issues, 2002, 13(3): 421-430.
pmid: 12151995 |
[84] |
Babl FE, Franklin D, Schlapbach LJ, et al. Enteral hydration in high-flow therapy for infants with bron-chiolitis: Secondary analysis of a randomised trial[J]. J Paediatr Child Health, 2020, 56(6): 950-955.
doi: 10.1111/jpc.v56.6 |
[85] |
Slain KN, Martinez-Schlurmann N, Shein SL, et al. Nutrition and high-flow nasal cannula respiratory support in children with bronchiolitis[J]. Hosp Pediatr, 2017, 7(5): 256-262.
doi: 10.1542/hpeds.2016-0194 pmid: 28424243 |
[86] |
Oakley E, Borland M, Neutze J, et al. Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: a randomised trial[J]. Lancet Resp Med, 2013, 1(2): 113-120.
doi: 10.1016/S2213-2600(12)70053-X pmid: 24429091 |
[87] |
van Steensel-Moll HA, Hazelzet JA, van der Voort E, et al. Excessive secretion of antidiuretic hormone in infections with respiratory syncytial virus[J]. Arch Dis Child, 1990, 65(11): 1237-1239.
pmid: 2123382 |
[88] | Kausar S, Said Khan F, Ishaq Mujeeb Ur Rehman M, et al. A review: mechanism of action of antiviral drugs[J]. Int J Immunopathol Pharmacol, 2021, 35: 20587384211002621. |
[89] |
Mooney K, Melvin M, Douglas T. Ribavirin: the need for exposure precautions[J]. Clin J Oncol Nurs, 2014, 18(5): E93-E96.
doi: 10.1188/14.CJON.E93-E96 |
[90] |
Tejada S, Martinez-Reviejo R, Karakoc HN, et al. Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis[J]. Adv Ther, 2022, 39(9): 4037-4051.
doi: 10.1007/s12325-022-02256-5 pmid: 35876973 |
[91] |
Wongsurakiat P, Sunhapanit S, Muangman N. Respiratory syncytial virus-associated acute respiratory illness in adult non-immunocompromised patients: outcomes, determinants of outcomes, and the effect of oral ribavirin treatment[J]. Influenza Other Respir Viruses, 2022, 16(4): 767-779.
doi: 10.1111/irv.v16.4 |
[92] |
Martín-Cerezuela M, Cuéllar-Monreal MJ, Monte-Boquet E, et al. Oral ribavirin for treatment of respiratory syncytial virus in lung transplantation recipients[J]. Transplant Proc, 2021, 53(9): 2702-2705.
doi: 10.1016/j.transproceed.2021.08.037 |
[93] | Wu Z. A phase 3 pivotal study of efficacy and safety of oral ziresovir in RSV-Infected Hospitalized Infants[C]// International RSV Symposium. Belfast: International Chamber of Commerce, 2022. |
[94] |
Ahmad A, Eze K, Noulin N, et al. EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge[J]. NEJM, 2022, 386(7): 655-666.
doi: 10.1056/NEJMoa2108903 |
[95] | DeVincenzo J, Tait D, Efthimiou J, et al. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein[J]. Antimicro Agents Chemother, 2020, 64(2): e01884-19. |
[96] |
Huntjens DRH, Ouwerkerk-Mahadevan S, Brochot A, et al. Population pharmacokinetic modeling of JNJ-53718678, a novel fusion inhibitor for the treatment of respiratory syncytial virus: results from a phase i, double-blind, randomized, placebo-controlled first-in-human study in healthy adult subjects[J]. Clin Pharmacokinet, 2017, 56(11): 1331-1342.
doi: 10.1007/s40262-017-0522-8 pmid: 28238203 |
[97] | Stevens M, Rusch S, DeVincenzo J, et al. Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study[J]. J Infect Dis Med, 2018, 218(5): 748-756. |
[98] |
Cunningham S, Piedra PA, Martinon-Torres F, et al. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial[J]. Lancet Respir Med, 2021, 9(1): 21-32.
doi: 10.1016/S2213-2600(20)30320-9 pmid: 33002427 |
[99] | Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children[J]. Cochrane Database Syst Rev, 2013, 2013(6): CD004878. |
[100] |
Van Woensel JBM, Vyas H. Dexamethasone in children mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus: a randomized controlled trial[J]. Crit Care Med, 2011, 39(7): 1779-1783.
doi: 10.1097/CCM.0b013e318218a030 pmid: 21460709 |
[101] |
Corneli HM, Zorc JJ, Mahajan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis[J]. NEJM, 2007, 357(4): 331-339.
doi: 10.1056/NEJMoa071255 |
[102] |
Plint AC, Johnson DW, Patel H, et al. Epinephrine and dexamethasone in children with bronchiolitis[J]. NEJM, 2009, 360(20): 2079-2089.
doi: 10.1056/NEJMoa0900544 |
[103] |
Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis[J]. Arch Dis Child, 2000, 82(2): 126-130.
pmid: 10648365 |
[104] |
Ermers MJJ, Rovers MM, van Woensel JB, et al. The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial[J]. BMJ, 2009, 338: b897.
doi: 10.1136/bmj.b897 |
[105] |
Alansari K, Sakran M, Davidson BL, et al. Oral dexa-methasone for bronchiolitis: a randomized trial[J]. Pediatrics, 2013, 132(4): e810-e816.
doi: 10.1542/peds.2012-3746 |
[106] | Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis[J]. Cochrane Database Syst Rev, 2014, 2014(6): CD001266. |
[107] |
Cai Z, Lin Y, Liang J. Efficacy of salbutamol in the treatment of infants with bronchiolitis: a meta-analysis of 13 studies[J]. Medicine, 2020, 99(4): e18657.
doi: 10.1097/MD.0000000000018657 |
[108] |
Andina Martínez D, Escalada Pellitero S, Viaño Nogueira P, et al. Decrease in the use of bronchodilators in the management of bronchiolitis after applying improvement initiatives[J]. Anales De Pediatria, 2022, 96(6): 476-484.
doi: 10.1016/j.anpede.2021.05.014 pmid: 35644761 |
[109] | Chandelia S, Kumar D, Chadha N, et al. Magnesium sulphate for treating acute bronchiolitis in children up to two years of age[J]. Cochrane Database Syst Rev, 2020, 12(12): CD012965. |
[110] |
Debbarma R, Khera D, Singh S, et al. Nebulized magnesium sulphate in bronchiolitis: a randomized controlled trial[J]. Indian J Pediatr, 2021, 88(11): 1080-1085.
doi: 10.1007/s12098-021-03695-8 |
[111] | Midulla F, Nenna R, Scagnolari C, et al. How respiratory syncytial virus genotypes influence the clinical course in infants hospitalized for bronchiolitis[J]. J Infect Dis Med, 2019, 219(4): 526-534. |
[112] |
Hall CB, Powell KR, Schnabel KC, et al. Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial viral infection[J]. J Pediatr, 1988, 113(2): 266-271.
doi: 10.1016/S0022-3476(88)80263-4 |
[113] |
Hishiki H, Ishiwada N, Fukasawa C, et al. Incidence of bacterial coinfection with respiratory syncytial virus bronchopulmonary infection in pediatric inpatients[J]. J Infect Chemother, 2011, 17(1): 87-90.
doi: 10.1007/s10156-010-0097-x pmid: 20700753 |
[114] |
Oakley E, Brys T, Borland M, et al. Medication use in infants admitted with bronchiolitis[J]. Emerg Med Australas, 2018, 30(3): 389-397.
doi: 10.1111/1742-6723.12968 pmid: 29573212 |
[115] | Farley R, Spurling GKP, Eriksson L, et al. Antibiotics for bronchiolitis in children under two years of age[J]. Cochrane Database Syst Rev, 2014(10): CD005189. |
[116] | McCallum GB, Plumb EJ, Morris PS, et al. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children[J]. Cochrane Database Syst Rev, 2017, 8(8): CD009834. |
[117] |
Flood RG, Badik J, Aronoff SC. The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children[J]. J Pediatr Infect Dis, 2008, 27(2): 95-99.
doi: 10.1097/INF.0b013e318157aced |
[118] | 中华医学会儿科学分会医院感染管理与控制专业委员会. 血清降钙素原检测在儿童感染性疾病中的临床应用专家共识[J]. 中华儿科杂志, 2019, 57(1): 9-15. |
[119] |
Munoz FM. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?[J]. Curr Opin Infect Dis, 2015, 28(3): 221-224.
doi: 10.1097/QCO.0000000000000161 pmid: 25918956 |
[120] |
Pantaleo G, Correia B, Fenwick C, et al. Antibodies to combat viral infections: development strategies and progress[J]. Nat Rev Drug Discov, 2022, 21(9): 676-696.
doi: 10.1038/s41573-022-00495-3 pmid: 35725925 |
[121] |
Scott LJ, Lamb HM. Palivizumab[J]. Drugs, 1999, 58(2): 305-311.
pmid: 10473022 |
[122] |
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection[J]. Pediatrics, 2014, 134(2): 415-420.
doi: 10.1542/peds.2014-1665 pmid: 25070315 |
[123] |
Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age[J]. Pediatrics, 2013, 132(2): e341-348.
doi: 10.1542/peds.2013-0303 |
[124] |
Keam SJ. Nirsevimab: first approval[J]. Drugs, 2023, 83(2): 181-187.
doi: 10.1007/s40265-022-01829-6 |
[125] |
Muller WJ, Madhi SA, Seoane Nuñez B, et al. Nirsevimab for prevention of rsv in term and late-preterm infants[J]. NEJM, 2023, 388(16): 1533-1534.
doi: 10.1056/NEJMc2214773 |
[126] |
Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants[J]. NEJM, 2022, 386(9): 837-846.
doi: 10.1056/NEJMoa2110275 |
[127] | Kieffer A, Beuvelet M, Sardesai A, et al. Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all us infants in their first rsv season: a static model[J]. J Infect Dis Med, 2022, 226(Suppl 2): S282-S292. |
[128] |
Hodgson D, Koltai M, Krauer F, et al. Optimal respiratory syncytial virus intervention programmes using nirsevimab in england and wales[J]. Vaccine, 2022, 40(49): 7151-7157.
doi: 10.1016/j.vaccine.2022.10.041 pmid: 36328884 |
[129] |
Messina A, Germano C, Avellis V, et al. New strategies for the prevention of respiratory syncytial virus (RSV)[J]. Early Human Develop, 2022, 174: 105666.
doi: 10.1016/j.earlhumdev.2022.105666 |
[130] |
Dolgin E. Antibody therapies set to transform respiratory syncytial virus prevention for babies[J]. Nature, 2023, 621(7980): S55-S57.
doi: 10.1038/d41586-023-02957-z |
[131] | 宋钰, 都丽萍, 屈静晗, 等. 静脉注射用免疫球蛋白药学特点和临床应用探索[J]. 中国药学杂志, 2021, 56(5): 417-421. |
[132] |
Shan YH, Zhang YG, Zhang JH, et al. The physiological effects of human immunoglobulin on severe bronchiolitis patients before and after treatment[J]. Hum Vaccin Immunother, 2015, 11(11): 2647-2653.
doi: 10.1080/21645515.2015.1080401 |
[133] |
Boukhvalova M, Blanco JCG, Falsey AR, et al. Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus[J]. Bone Marrow Transplant, 2016, 51(1): 119-126.
doi: 10.1038/bmt.2015.212 |
[134] | Sanders SL, Agwan S, Hassan M, et al. Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection[J]. Cochrane Database Syst Rev, 2019, 8(8): CD009417. |
[135] | Fuller HL, Del Mar CB. WITHDRAWN: Immunoglobulin treatment for respiratory syncytial virus infection[J]. Cochrane Database Syst Rev, 2010(9): CD004883. |
[136] |
Boschetti N, Stucki M, Späth PJ, et al. Virus safety of intravenous immunoglobulin: future challenges[J]. Clin Rev Allergy Immunol, 2005, 29(3): 333-344.
doi: 10.1385/CRIAI:29:3 |
[137] | Nam HH, Ison MG. Respiratory syncytial virus infection in adults[J]. BMJ, 2019, 366: l5021. |
[138] |
Van Brusselen D, De Troeyer K, Ter Haar E, et al. Bronchiolitis in COVID-19 times: a nearly absent disease?[J]. Eur J Pediatr, 2021, 180(6): 1969-1973.
doi: 10.1007/s00431-021-03968-6 pmid: 33517482 |
[139] |
Yang Q, Xiao X, Gu X, et al. Surveillance of common respiratory infections during the COVID-19 pandemic demonstrates the preventive efficacy of non-pharmaceutical interventions[J]. Int J Infect Dis, 2021, 105: 442-447.
doi: 10.1016/j.ijid.2021.02.027 pmid: 33582375 |
[140] |
Yeo KT, Yung CF, Chiew LC, et al. Universal mask policy in the neonatal unit to reduce respiratory viral infections[J]. Clin Infect Dis, 2017, 64(6): 817.
doi: 10.1093/cid/ciw842 pmid: 27986668 |
[141] |
Sung AD, Sung JAM, Thomas S, et al. Universal mask usage for reduction of respiratory viral infections after stem cell transplant: a prospective trial[J]. Clin Infect Dis, 2016, 63(8): 999-1006.
doi: 10.1093/cid/ciw451 pmid: 27481873 |
[142] |
Kisielinski K, Giboni P, Prescher A, et al. Is a mask that covers the mouth and nose free from undesirable side effects in everyday use and free of potential hazards?[J]. Int J Environ Res Pub Health, 2021, 18(8): 4344.
doi: 10.3390/ijerph18084344 |
[143] |
Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment[J]. Clin Microbiol Rev, 2017, 30(1): 277-319.
pmid: 27903593 |
[144] |
Qiu X, Xu S, Lu Y, et al. Development of mRNA vaccines against respiratory syncytial virus (RSV)[J]. Cytokine Growth Factor Rev, 2022, 68: 37-53.
doi: 10.1016/j.cytogfr.2022.10.001 |
[145] |
Mazur NI, Terstappen J, Baral R, et al. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape[J]. Lancet Infect Dis, 2023, 23(1): e2-e21.
doi: 10.1016/S1473-3099(22)00291-2 |
[146] | Shi T, Ooi Y, Zaw EM, et al. Association between respiratory syncytial virus-associated acute lower respiratory infection in early life and recurrent wheeze and asthma in later childhood[J]. J Infect Dis Med, 2020, 222(Suppl 7): S628-S633. |
[147] |
Coutts J, Fullarton J, Morris C, et al. Association between respiratory syncytial virus hospitalization in infancy and childhood asthma[J]. Pediatr Pulmonol, 2020, 55(5): 1104-1110.
doi: 10.1002/ppul.v55.5 |
[148] |
Quinn LA, Shields MD, Sinha I, et al. Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review[J]. Syst Rev, 2020, 9(1): 269.
doi: 10.1186/s13643-020-01527-y pmid: 33239107 |
[149] |
Rosas-Salazar C, Chirkova T, Gebretsadik T, et al. Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study[J]. Lancet, 2023, 401(10389): 1669-1680.
doi: 10.1016/S0140-6736(23)00811-5 pmid: 37086744 |
[150] | Verwey C, Ramocha L, Laubscher M, et al. Pulmonary sequelae in 2-year-old children after hospitalisation for respiratory syncytial virus lower respiratory tract infection during infancy: an observational study[J]. BMJ Open Respir Res, 2023, 10(1): e001618. |
[151] |
Qin L, Qiu K Z, Hu C P, et al. Bronchial epithelial cells promote the differentiation of Th2 lymphocytes in airway microenvironment through Jagged/Notch-1 signaling after RSV infection[J]. Int Arch Allergy Immunol, 2019, 179(1): 43-52.
doi: 10.1159/000495581 |
[152] |
Schuurhof A, Janssen R, de Groot H, et al. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze[J]. Respir Res, 2011, 12(1): 121.
doi: 10.1186/1465-9921-12-121 |
[153] |
Rossi GA, Colin AA. Respiratory syncytial virus-Host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life[J]. Pediatr Allergy Immunol, 2017, 28(4): 320-331.
doi: 10.1111/pai.2017.28.issue-4 |
[154] |
Tan YR, Peng D, Chen CM, et al. Nonstructural protein-1 of respiratory syncytial virus regulates HOX gene expression through interacting with histone[J]. Mol Biol Rep, 2013, 40(1): 675-679.
doi: 10.1007/s11033-012-2107-9 |
[155] |
Kenmoe S, Atenguena Okobalemba E, et al. Association between early viral lower respiratory tract infections and subsequent asthma development[J]. World J Crit Care Med, 2022, 11(4): 298-310.
doi: 10.5492/wjccm.v11.i4.298 pmid: 36051944 |
[156] |
Scheltema NM, Nibbelke EE, Pouw J, et al. Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial[J]. Lancet Respir Med, 2018, 6(4): 257-264.
doi: 10.1016/S2213-2600(18)30055-9 pmid: 29500030 |
[157] |
Korppi M, Piippo-Savolainen E, Korhonen K, et al. Respiratory morbidity 20 years after RSV infection in infancy[J]. Pediatr Pulmonol, 2004, 38(2): 155-160.
doi: 10.1002/ppul.v38:2 |
[158] |
Brunwasser SM, Snyder BM, Driscoll AJ, et al. Assessing the strength of evidence for a causal effect of respiratory syncytial virus lower respiratory tract infections on subsequent wheezing illness: a systematic review and meta-analysis[J]. Lancet Respir Med, 2020, 8(8): 795-806.
doi: 10.1016/S2213-2600(20)30109-0 pmid: 32763206 |
No related articles found! |
|